CGI Receives Approval to Provide Oncology Testing for Patients in California
News Jan 05, 2015
Cancer Genetics, Inc has announced that its CLIA-certified, CAP-accredited reference laboratory has received licensure from the California Department of Health. The California Clinical Laboratory License will allow the company to provide its state-of-the art oncology testing services for patient samples from the state of California.
"Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth. CGI is well positioned to continue to empower the personalization of treatment by providing our unique technologies and tests for a region that demands innovation and access to world-class medical technology," said Panna Sharma, CEO of Cancer Genetics. "Although cancer rates in the State of California are relatively stable, there is a tremendous need to improve the costs associated with patient management and therapeutic selection, and provide molecular insights that can enable earlier and more comprehensive diagnosis. We will work closely with our partners, and with our sales and commercial team, to add value for clinicians, cancer centers, and regional providers to enable better, more informed diagnosis and prognosis of cancer."
In 2014, more than 171,000 new cases of cancer were diagnosed in the State of California, representing more than 10 percent of the total cancer incidence in the United States. The company believes that its proprietary tests and complete programs for Non-Hodgkin's Lymphoma (NHL) and leukemia will be of particular benefit to California, where more than 6,800 new patients are diagnosed with NHL, and 4,300 additional patients are diagnosed with leukemia each year.
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE